• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Lucy Scientific Discovery's Alternative Mental Health Treatments to Provide Opportunity to Improve Mental Health

    10/18/23 7:00:00 AM ET
    $LSDI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LSDI alert in real time by email

    DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (NASDAQ:LSDI) is a pioneer in alternative mental health treatments and looking to grab its share of the leadership mantle, as it uncovers alternative mental health treatments.

    From herbal remedies to psychedelics, like psilocybin and MDMA, Lucy Scientific is working to provide the ingredients for groundbreaking mental health therapies and are well positioned to support this space as it continues to grow.

    Mental Health Refocus

    Mental health issues and treatments are nearly as old as mankind, but, as mental health disorders reach epidemic proportions, affecting millions of Americans every year, it seems that the treatments are finally rapidly evolving.

    While Selective Serotonin Reuptake Inhibitors (SSRIs) are usually the go to prescription, they don't work for everyone and, as more experts recognize the debilitating side effects for many users, they are falling out of favor and forced many of those former patients to seek alternative treatments to fill the therapeutic void.

    According to The Business Research Company, the Global Antidepressants market is growing at an annual rate of 5.9% and hit US $17.4 Billion, in 2023. The market size for these drugs shows not only the widespread medical prescription use, but the public acceptance of these treatments.

    The Centers for Disease Control and Prevention estimated that more than 37 million Americans take antidepressants and SSRIs are just one of the prescribed options, but they account for more than 45 million units dispensed in 2022.

    The limitations of SSRIs

    SSRIs function by manipulating serotonin levels in the brain and can be effective for some, but, according to the Journal of Affective Disorders, they consistently fail to address the underlying issues for more than 30% of consumers. Complaints include a range of side effects from sexual dysfunction to emotional numbing for a significant percentage of users.

    Giving rise to alternative medicine solutions

    Lucy is one of a handful of companies in this sector that are garnering lots of attention, but the wealthy billionaire investors, such as Peter Theil and Ryan Cohen, have recently put their money to work in alternative mind medicines, bringing the credibility needed to prove the industry is ripe for innovation and growth.

    Theil invested in Compass Pathways; a company focused on psilocybin research for treatment resistant depression, as reported on CNBC, and is one of many famous investors whose support indicate that this is nothing short of the beginnings of a new mega trend.

    Cannabis Legislation: The Gateway to Alternative Treatments

    The cannabis legalization wave continues to sweep across the United States and has done more than just open doors for the marijuana industry. Cannabis legislation has become a sort of "gateway legislation", paving the way for a more widespread acceptance and exploration of alternative mental health treatments.

    Many of the states that have led the way in cannabis legalization are the same states pushing the legalization envelope for other alternative medicines, such as psilocybin and MDMA. The destigmatization of cannabis through legislative action set the precedent, encouraging research and investment into other psychoactive substances for medicinal use.

    Legislative changes, like Oregon's Measure 109, are creating a more welcoming environment for alternative treatments. The Food and Drug Administration announced that several are even undergoing FDA-approved clinical trials.

    Accordingly, we witnessed completion of a second phase 3 study on MDMA, or ecstasy, which was successful at meeting the endpoints in treating PTSD. The MAPS study completion allows for the application submission for approval from the FDA, which is expected to be granted sometime in 2024.

    Lucy Scientific Discoveries is positioned to provide authorized support for many of these growing industries.

    Another example, in California, where medical marijuana has been legal since 1996, there are now active movements to decriminalize psychedelics and Governor Newsom released a statement "California should immediately begin work to set up regulated treatment guidelines — replete with dosing information, therapeutic guidelines, rules to prevent against exploitation during guided treatments, and medical clearance of no underlying psychoses."

    The progress made in cannabis legislation has undeniably made it easier for companies like Lucy Scientific and investors to approach alternative therapies with a level of credibility and confidence that was previously unattainable.

    More States are exploring ways to turn this movement into a Wave.

    Legislation to allow research on the therapeutic benefits psilocybin is under consideration in states across the political spectrum this year, including Arizona, Hawaii, and Oklahoma. The Associated Press reported that legislation to legalize therapeutic use or create pilot programs is under consideration in states including California, Connecticut, New York, Utah, and Washington.

    Will the Feds finally fix banking for Cannabis and Alternative medicines?

    The United States Senate Banking Committee voted 14-9 to pass the Secure and Fair Enforcement Regulation Banking Act (SAFER Banking Act). This bill will allow legal cannabis businesses access to financial banking institutions, which, in turn, opens up access to growth capital, insurance, and other much needed financial services afforded to any other industry.

    This bill is likely to pass, as the Biden administration received support from some previously hostile bureaucrats to loosen marijuana restrictions. The Department of Health and Human Services asked the Drug Enforcement Agency to reclassify cannabis upon a review of its classification under the Controlled Substances Act. The DEA will consider moving marijuana down to a Schedule III drug, alongside ketamine and other drugs that have moderate to low potential for physical or psychological dependence. The recommendation, however, will not de-schedule marijuana. A decision is likely to come before the 2024 presidential election, Roth MKM analyst Scott Fortune wrote in a Thursday note to clients (CNBC).

    Bridging The Gap

    With more than 30% of patients who use SSRIs seeking alternative treatments, the key is to be on the leading edge of safe and effective replacement treatments or to serve as a complimentary treatment for SSRI's and other medicines.

    With the backing of high-profile investors and an evolving legislative landscape, companies like Lucy Scientific Discovery Inc. (NASDAQ:LSDI) are poised to lead this revolution.

    Connect with 24/7 Market News:

    www.247marketnews.com  

    https://twitter.com/247MarketNewsHQ

    https://www.facebook.com/247MarketNewsHQ/

    About 24/7 Market News

    As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information.  24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.

    DISCLAIMER:

    24/7 Market News (24/7MN) is a third-party publisher and online news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ, and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7 MN is not affiliated with any company written about in this release and owns no shares of stock. 24/7MN's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.

    For more information visit https://www.247marketnews.com/lsdi-lucy-scientific-discovery/

    The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable.

    Cautionary Statement Regarding Forward Looking Information

    Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

    CONTACT:

    24/7 Market News

    [email protected]



    Primary Logo

    Get the next $LSDI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LSDI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LSDI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lucy Scientific Discovery Inc. Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

      Lucy Scientific Discovery Inc. (NASDAQ:LSDI), a Company dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes, and enhancing well-being for individuals worldwide, announces that it has a hearing scheduled for June 25, 2024 before a Nasdaq Hearings Panel (the "Panel") regarding its plan to regain compliance with Nasdaq Listing Rule 5550(b) (the "Stockholders' Equity Rule"). On May 21, 2024, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") that, per Nasdaq Listing Rule 5250(c)(1) (the "Filings Rule"), the Company is delinquent in filing its Quarterly Report on Form 1

      5/28/24 4:05:00 PM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lucy Scientific Discovery Inc. Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

      Lucy Scientific Discovery Inc. (NASDAQ:LSDI), a Company dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes, and enhancing well-being for individuals worldwide announces that the Company will effect a one-for-ten (1-10) reverse split of its common shares. The Company is effecting the reverse split in an effort to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The reverse share split will become effective on Monday, February 26, 2024 (the "Effective Date"), and the shares are expected to begin trading on the split-adjusted b

      2/16/24 4:05:00 PM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lucy Scientific Discovery's Alternative Mental Health Treatments to Provide Opportunity to Improve Mental Health

      DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (NASDAQ:LSDI) is a pioneer in alternative mental health treatments and looking to grab its share of the leadership mantle, as it uncovers alternative mental health treatments. From herbal remedies to psychedelics, like psilocybin and MDMA, Lucy Scientific is working to provide the ingredients for groundbreaking mental health therapies and are well positioned to support this space as it continues to grow. Mental Health Refocus Mental health issues and treatments are nearly as old as mankind, but, as mental health disorders reach epidemic proportions, affecting millions of Americans every year, it seems that the tre

      10/18/23 7:00:00 AM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LSDI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Mcelvany Christopher acquired $284,167 worth of shares (118,403 units at $2.40) and converted options into 366,187 shares

      4 - Lucy Scientific Discovery, Inc. (0001865127) (Issuer)

      2/15/23 9:28:18 PM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Kazeminy Assad J acquired $204,000 worth of shares (85,000 units at $2.40)

      4 - Lucy Scientific Discovery, Inc. (0001865127) (Issuer)

      2/15/23 8:56:34 PM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Susin Livio acquired $22,342 worth of shares (9,309 units at $2.40), increasing direct ownership by 7% to 134,809 units

      4 - Lucy Scientific Discovery, Inc. (0001865127) (Issuer)

      2/15/23 8:55:48 PM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LSDI
    SEC Filings

    See more
    • Lucy Scientific Discovery Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Lucy Scientific Discovery, Inc. (0001865127) (Filer)

      7/1/24 8:30:14 AM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lucy Scientific Discovery Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Lucy Scientific Discovery, Inc. (0001865127) (Filer)

      5/28/24 5:19:04 PM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Lucy Scientific Discovery Inc.

      NT 10-Q - Lucy Scientific Discovery, Inc. (0001865127) (Filer)

      5/15/24 5:24:31 PM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LSDI
    Financials

    Live finance-specific insights

    See more
    • Lucy Scientific Discovery Expands its Reach in the Global Wellness Market with BlueSky Wellness Acquisition

      VANCOUVER, BC / ACCESSWIRE / September 12, 2023 / Lucy Scientific Discovery Inc. (NASDAQ:LSDI), a publicly traded company focused on the development, sale, delivery, and manufacturing of psychotropic products, recently announced its acquisition of all High Times IP and brand assets - has just announced the acquisition of BlueSky Wellness Inc., along with the full BlueSky portfolio of brands adding psychotropic products to its catalog, expanding its footprint into the global wellness market. The BlueSky Wellness family of wellness focused ecommerce brands includes Keoni, Keoni Sport, Blush Wellness and AMMA Healing, which have generated over $20 million in revenue in each of the last two y

      9/12/23 11:20:00 PM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lucy Scientific Acquires High Times Intellectual Property, Including Existing Licensing Agreements in All-Stock Transaction

      VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. ("Lucy" or "the Company") (NASDAQ:LSDI), a leading psychotropic innovator announces the acquisition of the intellectual property (IP) of High Times, the most recognizable and iconic brand in the cannabis industry. This acquisition provides a stream of high-margin licensing and royalty income from the well-regarded High Times, Cannabis Cup, and 420.com brands, including their respective domain names.  Lucy will issue 19.9% of its outstanding stock to High Times and make payments semi-annually for the next 5 years based on EBITDA generated from the acquired IP, which can be settled with either s

      9/7/23 8:00:36 AM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LSDI
    Leadership Updates

    Live Leadership Updates

    See more
    • Lucy Scientific Discovery Inc. Taps Fortune 500 Veteran and Current Executive Chairman Richard Nanula as New CEO

      VANCOUVER, British Columbia, July 13, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (NASDAQ:LSDI), a leader and innovator in the psychotropic industry, announced the appointment of current Executive Chairman Richard Nanula as the new Chief Executive Officer, effective immediately. Nanula will retain his Chairman role while succeeding Chris McElvany as Chief Executive Officer, who will transition into a consulting role with the Company. Nanula brings to Lucy decades of senior leadership experience from several of the largest companies in the world having been a Senior Executive at The Walt Disney Company, Amgen, Colony Capital and Starwood Hotels and Resorts. Over the course of h

      7/13/23 9:00:00 AM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lucy Scientific Discovery Appoints Former B.C. Solicitor General Kash Heed as a Special Advisor

      VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. ("Lucy" or "The Company") (NASDAQ:LSDI), an early-stage psychedelics manufacturing company, announced today that former British Columbia Solicitor General Kash Heed has joined the company as a Special Advisor. Among other important contributions, Mr. Heed will apply his knowledge from decades of public service to help the company successfully navigate Canada's rapidly evolving drug policy landscape and growing budget focused on mental health and safe-supply programs. Mr. Heed started his public service 44 years ago with the Vancouver Police Department (VPD). With the VPD, he pioneered initia

      3/29/23 9:00:00 AM ET
      $LSDI
      Biotechnology: Pharmaceutical Preparations
      Health Care